Biorek is an Italian
biotechnology
company

Biorek is an Italian biotechnology company founded in Milan in 2019 by Alessandra Cinque, PhD, a biotechnology researcher, and Francesco Trevisani, MD, PhD, a nephrologist and researcher.

The company is focused on liquid biopsy-based molecular diagnostics for oncology and innovative laboratory consumables.

The company now aims to build its business model around two complementary but synergic biotech divisions: MiRECLE, dedicated to molecular kidney cancer diagnostic tests and ALCINEX, focused on innovative and breakthrough laboratory consumables.

The story of Biorek began with a research conducted by the two founders at IRCCS San Raffaele Hospital, where they investigated molecular signatures for kidney cancer assessment, an insidious and worldwide growing type of malignancy.

Then, the two entrepreneurs decided to bring together their scientific and clinical expertise and turn their academic research into a business, establishing Biorek. Today, Alessandra Cinque serves as President and Francesco Trevisani as CEO.

The initial goal of Biorek was to develop blood-based molecular tests to support kidney cancer screening, diagnosis and prognosis. This research led to MiRECLE, a test based on patented circulating microRNA panels and proprietary machine learning algorithms, currently undergoing scientific validation.
The development of this innovative test was supported by an international, multicentre observational clinical trial involving 1,000 participants, including patients with renal masses and controls. Biological samples collected from these participants were stored in a biobank containing approximately 22,000 biospecimens.

In 2026, a disrupted idea from the co-founder Cinque, inspired by her laboratory experience, led to the creation of ALCINEX, a new line of patented innovative laboratory consumables for research and diagnostic applications.
The first patented products in our portfolio are reagent reservoirs designed for manual multichannel pipetting and automated liquid handling, improving efficiency and precision while minimizing reagent and sample waste. Additional laboratory consumables will be introduced as we expand our product portfolio.

Today, the company is a registered Innovative SME, supported by an international shareholder base that includes private investors, companies and scientific institutions.
Since its foundation, Biorek raised €1.81 million across three equity funding rounds and secured more than €600,000 through Invitalia’s Smart&Start Italia programme.

Grant & Fundraising

11/2025

Third round fundraising: € 810 K

12/2023

Second round fundraising: € 500 K

10/2023

Lending Crowfunding campaign with Op-start platform; € 250 K

07/2020

Invitalia SMART and START seed investment for € 776 K

05/2019

First round fundraising; € 500 K

2017

2nd Prize, Open Accelerator Program, Z-Cube S.r.l. (Research Venture of Zambon Group), € 50 K seed investment.

Dott.ssa Cinque and Dott Trevisani as Team leaders